Fierce Biotech
Novo Nordisk inks $2.1B pact with Langer startup to boost oral drug delivery prowess
Following the launch of its Wegovy (semaglutide) pill at the beginning of the year, Novo Nordisk is committing as much as $2.1 billion to next-gen delivery mechanisms for its metabolic portfolio.
